TY - JOUR
T1 - Autologous Bone-Marrow vs. Peripheral Blood Mononuclear Cells Therapy for Peripheral Artery Disease in Diabetic Patients
AU - Yunir, Em
AU - Kurniawan, Farid
AU - Rezaprasga, Edo
AU - Wijaya, Ika Prasetya
AU - Suroyo, Indrati
AU - Matondang, Sahat
AU - Irawan, Cosphiadi
AU - Soewondo, Pradana
N1 - Funding Information:
The authors thank to Yully Astika Nugrahayning Aziza and Eni Iswati for their help in preparing the manuscript.
Publisher Copyright:
Copyright © 2021 by the Korean Society for Stem Cell Research
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021
Y1 - 2021
N2 - Diabetes mellitus (DM) remains one of the most important risk factors for peripheral artery disease (PAD), with approximately 20% of DM patients older than 40 years old are affected with PAD. The current standard management for severe PAD is endovascular intervention with or without surgical bypass. Unfortunately, up to 40% of patients are unable to undergo these revascularization therapies due to excessive surgical risk or adverse vascular side effects. Stem cell therapy has emerged as a novel therapeutic strategy for these ‘no-option’ patients. Several types of stem cells are utilized for PAD therapy, including bone marrow mononuclear cells (BMMNC) and peripheral blood mononuclear cells (PBMNC). Many studies have reported the safety of BMMNC and PBMNC, as well as its efficacy in reducing ischemic pain, ulcer size, pain-free walking distance, ankle-brachial index (ABI), and transcutaneous oxygen pressure (TcPO2). However, the capacity to establish the efficacy of reducing major amputation rates, amputation free survival, and all-cause mortality is limited, as shown by several randomized placebo-controlled trials. The present literature review will focus on comparing safety and efficacy between BMMNC and PBMNC as cell-based management in diabetic patients with PAD who are not suitable for revascularization therapy.
AB - Diabetes mellitus (DM) remains one of the most important risk factors for peripheral artery disease (PAD), with approximately 20% of DM patients older than 40 years old are affected with PAD. The current standard management for severe PAD is endovascular intervention with or without surgical bypass. Unfortunately, up to 40% of patients are unable to undergo these revascularization therapies due to excessive surgical risk or adverse vascular side effects. Stem cell therapy has emerged as a novel therapeutic strategy for these ‘no-option’ patients. Several types of stem cells are utilized for PAD therapy, including bone marrow mononuclear cells (BMMNC) and peripheral blood mononuclear cells (PBMNC). Many studies have reported the safety of BMMNC and PBMNC, as well as its efficacy in reducing ischemic pain, ulcer size, pain-free walking distance, ankle-brachial index (ABI), and transcutaneous oxygen pressure (TcPO2). However, the capacity to establish the efficacy of reducing major amputation rates, amputation free survival, and all-cause mortality is limited, as shown by several randomized placebo-controlled trials. The present literature review will focus on comparing safety and efficacy between BMMNC and PBMNC as cell-based management in diabetic patients with PAD who are not suitable for revascularization therapy.
KW - Bone marrow mononuclear cells
KW - Diabetes mellitus
KW - Peripheral artery disease
KW - Peripheral blood mononuclear cells
KW - Stem cell therapy
UR - http://www.scopus.com/inward/record.url?scp=85102786540&partnerID=8YFLogxK
U2 - 10.15283/ijsc20088
DO - 10.15283/ijsc20088
M3 - Article
AN - SCOPUS:85102786540
SN - 2005-3606
VL - 14
SP - 21
EP - 32
JO - International Journal of Stem Cells
JF - International Journal of Stem Cells
IS - 1
ER -